|Bid||19.04 x 1200|
|Ask||24.50 x 3000|
|Day's Range||19.17 - 19.43|
|52 Week Range||18.11 - 25.48|
|Beta (3Y Monthly)||0.59|
|PE Ratio (TTM)||159.26|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's a roundup of top developments in the biotech space over the last 24 hours: No biotech stocks hit 52-week highs on Thursday. Down In The Dumps (Biotech stocks hitting 52-week lows on April 17) ABIOMED, ...
The sale is expected to close by the end of May. Once that occurs, 330 to 350 AngioDynamics employees are expected to join Medline Industries Inc., a privately-held company headquartered near Chicago.
Today we'll evaluate AngioDynamics, Inc. (NASDAQ:ANGO) to determine whether it could have potential as an investment idea. Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how e...
Despite strength in the VIT business, AngioDynamics (ANGO) exited third-quarter fiscal 2019 on a tepid note, with both earnings and revenues missing estimates.
AngioDynamics (ANGO) delivered earnings and revenue surprises of -13.64% and -2.44%, respectively, for the quarter ended February 2019. Do the numbers hold clues to what lies ahead for the stock?
The Latham, New York-based company said it had profit of 2 cents per share. Earnings, adjusted for one-time gains and costs, were 19 cents per share. The medical device maker posted revenue of $86.3 million ...
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at attractive prices, your portfolio returns could exceed the averageRead More...
Expanding customer base of the NanoKnife platform is likely to fortify AngioDynamics' (ANGO) foothold in the Medical Instruments space.
Inogen (INGN) gains from solid direct-to-consumer revenues in Q4; strong business-to-business revenues in the United States.
OPKO Health (OPK) witnesses sluggishness in the Products revenues segment in Q4. However, contribution from RAYALDEE has been significant in the quarter.